我国新冠病毒灭活疫苗获批进入临床试验

The two vaccines are China's first batch of COVID-19 inactivated vaccines that have obtained clinical trial approval. Using killed pathogenic microorganisms for enhancing the immunogenicity, the vaccines have advantages of mature production process, controllable quality standards and wide protection range.
此次获批进入临床试验的两款灭活疫苗是我国首批获得临床研究批件的新冠病毒灭活疫苗，是一种杀死病原微生物但仍保持其免疫原性的疫苗，具有生产工艺成熟、质量标准可控、保护范围广等优点。

They can be used for large-scale vaccination, and their safety and effectiveness can by judged by internationally accepted standards.
这两款疫苗可用于大规模接种，并且有国际通行标准来判断疫苗的安全性和有效性。

China has laid a solid foundation for research in inactivated vaccines, which has been widely used to fight hepatitis A, influenza, hand-foot-and-mouth disease and poliomyelitis.
我国的灭活疫苗有较好研究基础，甲肝灭活疫苗、流感灭活（裂解）疫苗、手足口病灭活疫苗、脊髓灰质炎灭活疫苗等均已广泛应用。